Arcus Biosciences Inc. (NYSE:RCUS) finished Friday with a subtraction of -$0.33 to close at $22.59, a downside of -1.44 percent. An average of 1,625,500 shares of common stock have been traded in the last five days. There was a gain of $3.55 in the past week, and it reached a new high 10 times over the past 12 months. The last 20 days have seen an average of 839,725 shares traded, while the 50-day average volume stands at 966,028.
RCUS stock has increased by 15.85% in the last month. The company shares reached their 1-month lowest point of $17.25 on 08/17/23. With the stock rallying to its 52-week high on 08/23/23, shares of the company touched a low of $15.70 and a high of $36.13 in 52 weeks. It has reached a new high 9 times so far this year and achieved 9.24% or $1.91 in price. In spite of this, the price is down -37.48% from the 52-week high.
Insider Transactions
RCUS stock investors should be aware that Arcus Biosciences Inc. (RCUS) stock had its last reported insider trading activity 29 days ago on Jul 28. In this transaction, the insider spent $911,250. Chief Accounting Officer, Azoy Alexander, disposed of 1,018 shares at a price of $20.41 on Jul 03. The insider now owns more than $20,777 worth of shares. Prior to that, Chief Operating Officer Jarrett Jennifer went on to Sale 12,437 shares at $19.12 each on Jun 22. An amount of $237,795 was transacted.
Valuation Metrics
Arcus Biosciences Inc. (RCUS) stock’s beta is 0.76. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 12.85, the price-to-book (PB) ratio at 2.92.
Financial Health
The quick ratio of Arcus Biosciences Inc. for the three months ended June 29 was 5.50, and the current ratio was 5.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $392.0 million compared to revenue of $112.0 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Arcus Biosciences Inc.’s return on assets was -22.10%.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$75.0 million in the quarter, while revenues were grew 11.16%. The analyst consensus anticipated Arcus Biosciences Inc.’s latest quarter earnings to come in at -$1.1 per share, but it turned out to be -$1.04, a 5.50% surprise. For the quarter, EBITDA amounted to -$85.0 million. At the end of the quarter ending June 29, Arcus Biosciences Inc.’s stock balance sheet showed total liabilities of 654.0 million. Shareholders own equity worth $74.5 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Arcus Biosciences Inc. (RCUS) price momentum. RSI 9-day as of the close on 25 August was 75.19%, suggesting the stock is Overbought, with historical volatility in this time frame at 106.37%.
As of today, RCUS’s price is $21.26 +18.64% or $3.55 from its 5-day moving average. RCUS is currently trading +13.52% higher than its 20-day SMA and +23.85% higher than its 100-day SMA. However, the stock’s current price level is +15.26% above the SMA50 and -1.57% below the SMA200.
The stochastic %K and %D were 68.09% and 70.21%, respectively, and the average true range (ATR) was 1.43. With the 14-day stochastic at 64.96% and the average true range at 1.26, the RSI (14) stands at 68.67%. The stock has reached 3.00 on the 9-day MACD Oscillator while the 14-day reading was at 3.57.
Analyst Ratings
BofA Securities launched coverage on Arcus Biosciences Inc. (NYSE: RCUS) in its analyst report released on November 18, 2022. The firm assigned the stock a Neutral rating. The consensus rating for Arcus Biosciences Inc. (RCUS) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell RCUS, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 10 others rate it as a “buy”.
What is RCUS’s price target for the next 12 months?
Analysts predict a range of price targets between $21.00 and $70.00, with a median target of $41.00. Taking a look at these predictions, the average price target given by analysts for Arcus Biosciences Inc. (RCUS) stock is $42.92.
